期刊文献+

尿液血管紧张素原与IgA肾病肾脏组织病理损伤的研究 被引量:1

Research of urine angiotensinogen and pathological damage of kidney tissue in IgA nephropathy
下载PDF
导出
摘要 目的探讨免疫球蛋白A(IgA)肾病患者尿液血管紧张素原(AGT)活性与临床及肾脏组织损伤的关系。方法 55例肾穿刺活检确诊的IgA肾病患者,分别测定其尿液AGT含量,并与临床、病理指标相比较分析。结果尿液AGT含量与24 h尿蛋白定量、肾小球、肾小管及肾间质积分呈正相关。随着病理评分的加重、尿蛋白定量的增加,尿液AGT原逐渐升高(P<0.05)。结论 IgA肾病患者尿液AGT可以反映临床及肾脏组织损伤的程度,可作为临床评估IgA肾病病情的无创指标之一。 Objective To investigate relationship between urine angiotensinogen (AGT) activity and clinical and kidney tissue damage in immune globulin A (IgA) nephropathy patients. Methods Urine AGT contents were detected in 55 renal biopsy diagnosed IgA nephropathy patients to compare and analyze with clinical and pathological indexes. Results Urine AGT content was positively correlation with 24 h urine protein content, glomerulus, kidney tubules and renal interstitium score. Increasing pathological score and urine protein content led to gradually increased urine AGT (P〈0.05). Conclusion Urine AGT reflects clinical and kidney tissue damage in IgA nephropathy patients, and it can be taken as one of noninvasive indexes in clinical evaluation of IgA nephropathy.
出处 《中国实用医药》 2016年第31期4-6,共3页 China Practical Medicine
基金 深圳市卫生计生系统科研项目(项目编号:201401031)
关键词 免疫球蛋白A肾病 血管紧张素原 尿蛋白定量 病理损伤 Immune globulin A nephropathy Angiotensinogen Urine protein quantitation Pathological damage
  • 相关文献

参考文献1

二级参考文献10

  • 1Kidney Disease : Improving Global Outcomes (KDIGO) Glomerulo- nephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis [ J 1. Kidney Int,2012, Suppl ( 2 ) : 139 - 274.
  • 2Reich HN,Troyanov S, Scholey JW, et al. Remission of proteinuria improves prognosis in IgAN [ J ]. J Am Soc lephrol,2007,18 ( 12 ) : 3177 -3183.
  • 3Cattran DC, Coppo R, Cook HT, et al. The Oxford classification of IgA nephropathy : rationale, clinicopathological correlations, and clas- sification [ J 1- Kidney Int 2009,76 (5) :534 - 545.
  • 4Praga M, Gutierrez E, Gonzalez E, et al. Treatment of IgAN with ACE inhibitors: A randomized and controlled trial [ J ]. J Am Soc Nephro1,2003,14 ( 6 ) : 1578 - 1583.
  • 5Li PKT, Leung CB, Chow KM, ct al. Hong Kong study using Valsar- tan in IgAN (HKVIN)- A double-blind randomized placebo-con- trolled study[ J l. Am J Kidney Dis,2006,47 (5) :751 -760.
  • 6Coppo R, Peruzzi L, Amorc A, ctal. IgACE : a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in chil- dren and young people with IgAN and moderate protcinuria [ J ]. J Am Soc Nephrol,2007,18 (6) : 1880 - 1888.
  • 7Pozzi C, Andrulli S, Del Vecchio L, et al. Corticosteroid effectiveness in IgAN : long-term results of a randomized, controlled trial [ J ]. J Am Soc Nephro1,2004,15 ( 1 ) : 157 - 163.
  • 8Manno C ,Torres DD, Rossini M, et al. Randomized controlled clini- cal trial of corticosteroids plus ACE-inhibitors with long-term follow- up in proteinuric IgAN [ J 1. Nephrol Dial Transplant, 2009,24 (12) :3694 -3701.
  • 9Lv J, Zhang H, Chert Y, et al. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgAN : a randomized controlled trial [ J 1. Am J Kidney Dis, 2009,53( 1 ) :26 -32.
  • 10Strippoli GF, Maione A, Schena FP, et al. IgAN :a disease in search of a large-scale clinical trial to reliably inform practice [ J 1. Am J Kidney Dis ,2009,53 ( 1 ) :5 - 8.

共引文献56

同被引文献13

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部